Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are th...
Gespeichert in:
| Veröffentlicht in: | Medical hypotheses 2020-07, Vol.140, p.109765-109765, Article 109765 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109765 |
|---|---|
| container_issue | |
| container_start_page | 109765 |
| container_title | Medical hypotheses |
| container_volume | 140 |
| creator | Pindiprolu, Sai Kiran S.S. Pindiprolu, Sai Harshini |
| description | Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing ‘old’ drugs to treat ‘new’ diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19. |
| doi_str_mv | 10.1016/j.mehy.2020.109765 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000540720800048CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306987720305892</els_id><sourcerecordid>2398162488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-803896b6daf4d03b9d353ed5fba8ecf134e6110fb6aef046c01050711a38439c3</originalsourceid><addsrcrecordid>eNqNkV-L1DAUxYMo7uzqF_BB-ihIx5u_TUEEqa6uLK4P6mtI09udDG2zNu3IfntTOg76IkJILsnv3JzkEPKMwpYCVa_22x5391sGbNkoCyUfkA2VnOWsKIqHZAMcVF7qojgj5zHuAaAUXD8mZ5xxRaXWG_LpS2fn6OsOsx7dzg4-9jELbfbZuy5E2_sGMxszO6Qx-YMfbZfZWxymNFs_xCmrbr5fvctp-YQ8am0X8elxvSDfLt9_rT7m1zcfrqq317kTUk65Bq5LVavGtqIBXpcNlxwb2dZWo2spF6gohbZWFlsQygEFCQWllmvBS8cvyJu1791c99i45CWZMnej7-14b4L15u-Twe_MbTiYgpaSAk8NXhwbjOHHjHEyvY8Ou84OGOZoGC81VUxonVC2om4MMY7Ynq6hYJYQzN4sIZglBLOGkETP_zR4kvz-9QS8XIGfWIc2Oo-DwxOWYpICCgY6VWKh9f_TlZ_s5MNQhXmYkvT1KsWUx8HjaI7yxo_oJtME_6-H_AKpu7kY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2398162488</pqid></control><display><type>article</type><title>Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19</title><source>ScienceDirect Journals (5 years ago - present)</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Pindiprolu, Sai Kiran S.S. ; Pindiprolu, Sai Harshini</creator><creatorcontrib>Pindiprolu, Sai Kiran S.S. ; Pindiprolu, Sai Harshini</creatorcontrib><description>Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing ‘old’ drugs to treat ‘new’ diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.</description><identifier>ISSN: 0306-9877</identifier><identifier>ISSN: 1532-2777</identifier><identifier>EISSN: 1532-2777</identifier><identifier>DOI: 10.1016/j.mehy.2020.109765</identifier><identifier>PMID: 32361588</identifier><language>eng</language><publisher>AMSTERDAM: Elsevier Ltd</publisher><subject>COVID-19 ; Drug discovery ; Life Sciences & Biomedicine ; Medicine, Research & Experimental ; Niclosamide ; Repurposing ; Research & Experimental Medicine ; SARS-CoV-2 ; Science & Technology</subject><ispartof>Medical hypotheses, 2020-07, Vol.140, p.109765-109765, Article 109765</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>45</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000540720800048</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c455t-803896b6daf4d03b9d353ed5fba8ecf134e6110fb6aef046c01050711a38439c3</citedby><cites>FETCH-LOGICAL-c455t-803896b6daf4d03b9d353ed5fba8ecf134e6110fb6aef046c01050711a38439c3</cites><orcidid>0000-0002-5400-4491</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mehy.2020.109765$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,28253,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32361588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pindiprolu, Sai Kiran S.S.</creatorcontrib><creatorcontrib>Pindiprolu, Sai Harshini</creatorcontrib><title>Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19</title><title>Medical hypotheses</title><addtitle>MED HYPOTHESES</addtitle><addtitle>Med Hypotheses</addtitle><description>Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing ‘old’ drugs to treat ‘new’ diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.</description><subject>COVID-19</subject><subject>Drug discovery</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, Research & Experimental</subject><subject>Niclosamide</subject><subject>Repurposing</subject><subject>Research & Experimental Medicine</subject><subject>SARS-CoV-2</subject><subject>Science & Technology</subject><issn>0306-9877</issn><issn>1532-2777</issn><issn>1532-2777</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqNkV-L1DAUxYMo7uzqF_BB-ihIx5u_TUEEqa6uLK4P6mtI09udDG2zNu3IfntTOg76IkJILsnv3JzkEPKMwpYCVa_22x5391sGbNkoCyUfkA2VnOWsKIqHZAMcVF7qojgj5zHuAaAUXD8mZ5xxRaXWG_LpS2fn6OsOsx7dzg4-9jELbfbZuy5E2_sGMxszO6Qx-YMfbZfZWxymNFs_xCmrbr5fvctp-YQ8am0X8elxvSDfLt9_rT7m1zcfrqq317kTUk65Bq5LVavGtqIBXpcNlxwb2dZWo2spF6gohbZWFlsQygEFCQWllmvBS8cvyJu1791c99i45CWZMnej7-14b4L15u-Twe_MbTiYgpaSAk8NXhwbjOHHjHEyvY8Ou84OGOZoGC81VUxonVC2om4MMY7Ynq6hYJYQzN4sIZglBLOGkETP_zR4kvz-9QS8XIGfWIc2Oo-DwxOWYpICCgY6VWKh9f_TlZ_s5MNQhXmYkvT1KsWUx8HjaI7yxo_oJtME_6-H_AKpu7kY</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Pindiprolu, Sai Kiran S.S.</creator><creator>Pindiprolu, Sai Harshini</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5400-4491</orcidid></search><sort><creationdate>20200701</creationdate><title>Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19</title><author>Pindiprolu, Sai Kiran S.S. ; Pindiprolu, Sai Harshini</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-803896b6daf4d03b9d353ed5fba8ecf134e6110fb6aef046c01050711a38439c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>COVID-19</topic><topic>Drug discovery</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, Research & Experimental</topic><topic>Niclosamide</topic><topic>Repurposing</topic><topic>Research & Experimental Medicine</topic><topic>SARS-CoV-2</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pindiprolu, Sai Kiran S.S.</creatorcontrib><creatorcontrib>Pindiprolu, Sai Harshini</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical hypotheses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pindiprolu, Sai Kiran S.S.</au><au>Pindiprolu, Sai Harshini</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19</atitle><jtitle>Medical hypotheses</jtitle><stitle>MED HYPOTHESES</stitle><addtitle>Med Hypotheses</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>140</volume><spage>109765</spage><epage>109765</epage><pages>109765-109765</pages><artnum>109765</artnum><issn>0306-9877</issn><issn>1532-2777</issn><eissn>1532-2777</eissn><abstract>Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing ‘old’ drugs to treat ‘new’ diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.</abstract><cop>AMSTERDAM</cop><pub>Elsevier Ltd</pub><pmid>32361588</pmid><doi>10.1016/j.mehy.2020.109765</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-5400-4491</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-9877 |
| ispartof | Medical hypotheses, 2020-07, Vol.140, p.109765-109765, Article 109765 |
| issn | 0306-9877 1532-2777 1532-2777 |
| language | eng |
| recordid | cdi_webofscience_primary_000540720800048CitationCount |
| source | ScienceDirect Journals (5 years ago - present); Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | COVID-19 Drug discovery Life Sciences & Biomedicine Medicine, Research & Experimental Niclosamide Repurposing Research & Experimental Medicine SARS-CoV-2 Science & Technology |
| title | Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T06%3A32%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plausible%20mechanisms%20of%20Niclosamide%20as%20an%20antiviral%20agent%20against%20COVID-19&rft.jtitle=Medical%20hypotheses&rft.au=Pindiprolu,%20Sai%20Kiran%20S.S.&rft.date=2020-07-01&rft.volume=140&rft.spage=109765&rft.epage=109765&rft.pages=109765-109765&rft.artnum=109765&rft.issn=0306-9877&rft.eissn=1532-2777&rft_id=info:doi/10.1016/j.mehy.2020.109765&rft_dat=%3Cproquest_webof%3E2398162488%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2398162488&rft_id=info:pmid/32361588&rft_els_id=S0306987720305892&rfr_iscdi=true |